| MiR-103a-3p targets the 5′ UTR of GPRC5A in pancreatic cells H Zhou, I Rigoutsos Rna 20 (9), 1431-1439, 2014 | 150 | 2014 |
| The emerging roles of GPRC5A in diseases. H Zhou, I Rigoutsos Oncoscience 1 (12), 765-776, 2014 | 65 | 2014 |
| GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR H Zhou, AG Telonis, Y Jing, NL Xia, L Biederman, M Jimbo, F Blanco, ... Cell death & disease 7 (7), e2294-e2294, 2016 | 38 | 2016 |
| Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b E Mogilyansky, P Clark, K Quann, H Zhou, E Londin, Y Jing, I Rigoutsos Frontiers in Genetics 7, 143, 2016 | 23 | 2016 |
| PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer Z Fang, H Shen, Q Xu, H Zhou, L Li, SY Yang, Z Zhu, J Tang Frontiers in Oncology 12, 2022 | 2 | 2022 |
| CBX3 promotes breast cancer progression and high level of CBX3 predicts poor prognosis in patients. K Yang, YL Wang, Z Zhu, XH Cao, MX Liang, D Xu, YJ Fei, SY Yang, ... Neoplasma, 220622N656-220622N656, 2023 | | 2023 |
| Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer Z Fang, YX Song, GQ Wo, HL Zhou, L Li, SY Yang, X Chen, J Zhang, ... Annals of Translational Medicine 10 (23), 2022 | | 2022 |
| Abstract A41: GPRC5A acts as a potent oncogene in pancreatic cancer H Zhou, A Telonis, Y Jing, M Jimbo, F Blanco, E Londin, J Brody, ... Cancer Research 76 (24_Supplement), A41-A41, 2016 | | 2016 |
| Systematic study of GPRC5A in the context of pancreatic ductal adenocarcinoma H Zhou Thomas Jefferson University, 2016 | | 2016 |
| Abstract| PDF| Full Text| Supplementary Table 1| Supplementary Table 2| https://doi. org/10.18632/oncoscience. 104 H Zhou, I Rigoutsos | | |
Isidore RigoutsosRichard W. Hevner Professor of Computational Medicine, Director Computational Medicine Center在 jefferson.edu 的电子邮件经过验证
